Department of Materials Engineering, Tarbiat Modares University, Tehran, Iran.
Department of Nanobiotechnology, New Technologies Research Group, Pasteur Institute of Iran, Tehran, Iran.
Sci Rep. 2023 Mar 18;13(1):4520. doi: 10.1038/s41598-023-31252-0.
Magnetic resonance imaging and computed tomography (CT) suffer from low contrast sensitivity and potential toxicity of contrast agents. To overcome these limitations, we developed and tested a new class of dual contrast agents based on polydopamine nanoparticles (PDA-NPs) that are functionalized and targeted with hyaluronic acid (HA). These nanoparticles (NPs) are chelated with Gd to provide suitable contrast. The targeted NPs were characterized through ultraviolet-visible spectroscopy (UV-vis), scanning electron microscopy (SEM), infrared Fourier transform (FTIR), and dynamic light scattering (DLS). The cytotoxicity was investigated on HEK293 cells using an MTT assay. The contrast property of synthesized Gd/PDA/HA was compared with Barium sulfate and Dotarem, as commercial contrast agents (CAs) for CT and MRI, respectively. The results illustrated that synthesized PDA-NPs have a spherical morphology and an average diameter of 72 nm. A distinct absorption peak around 280 nm in the UV-vis spectrum reported the self-polymerization of PDA-NPs. The HA coating on PDA-NPs was revealed through a shift in the FTIR peak of C=O from 1618 cm to 1635 cm. The Gd adsorption on PDA/HA-NPs was confirmed using an adsorption isotherm assay. The developed CA showed low in vitro toxicity (up to 158.98 µM), and created a similar contrast in MRI and CT when compared to the commercial agents. The r value for PDA/HA/Gd (6.5 (mg/ml) s) was more than Dotarem (5.6 (mg/ml) s) and the results of the hemolysis test showed that at concentrations of 2, 4, 6, and 10 mg/ml, the hemolysis rate of red blood cells is very low. Additionally, the results demonstrated that PDA/HA/Gd could better target the CD-expressing cancer cells than PDA/Gd. Thus, it can be concluded that lower doses of developed CA are needed to achieve similar contrast of Dotarem, and the developed CA has no safety concerns in terms of hemolysis. The stability of PDA/HA/Gd has also been evaluated by ICP-OES, zeta potential, and DLS during 3 days, and the results suggested that Gd-HA NPs were stable.
磁共振成像和计算机断层扫描(CT)的对比度灵敏度低,且对比剂存在潜在毒性。为了克服这些限制,我们开发并测试了一类基于聚多巴胺纳米粒子(PDA-NPs)的新型双对比剂,这些纳米粒子经过透明质酸(HA)的功能化和靶向修饰。这些纳米粒子(NPs)螯合了 Gd 以提供合适的对比度。通过紫外可见光谱(UV-vis)、扫描电子显微镜(SEM)、傅里叶变换红外光谱(FTIR)和动态光散射(DLS)对靶向 NPs 进行了表征。通过 MTT 测定法在 HEK293 细胞上研究了细胞毒性。将合成的 Gd/PDA/HA 的对比性能与硫酸钡和 Dotarem 进行了比较,硫酸钡和 Dotarem 分别是 CT 和 MRI 的商业对比剂(CA)。结果表明,合成的 PDA-NPs 具有球形形态,平均直径为 72nm。在 UV-vis 光谱中,280nm 左右的明显吸收峰表明 PDA-NPs 发生了自聚合。PDA-NPs 上的 HA 涂层通过 C=O 峰从 1618cm 到 1635cm 的移动得到证实。通过吸附等温线测定法证实了 Gd 在 PDA/HA-NPs 上的吸附。所开发的 CA 表现出低的体外毒性(高达 158.98µM),并且与商业试剂相比,在 MRI 和 CT 中产生相似的对比。PDA/HA/Gd(6.5(mg/ml)s)的 r 值大于 Dotarem(5.6(mg/ml)s),且溶血试验结果表明,在 2、4、6 和 10mg/ml 浓度下,红细胞的溶血率非常低。此外,结果表明 PDA/HA/Gd 可以更好地靶向表达 CD 的癌细胞,而不是 PDA/Gd。因此,可以得出结论,与 Dotarem 相比,开发的 CA 所需的剂量较低,且开发的 CA 在溶血方面没有安全性问题。通过 ICP-OES、zeta 电位和 DLS 在 3 天内对 PDA/HA/Gd 的稳定性进行了评估,结果表明 Gd-HA NPs 稳定。